The strategy of using mesenchymal stem cells (MSCs) as a living carrier for active delivery of
therapeutic agents targeting tumor sites has been attempted in a wide range of studies to …

The need for efficacious and non-toxic cancer therapies is paramount. Oncolytic viruses
(OVs) are showing great promise and are introducing new possibilities in cancer treatment …

Background Systemic administration of oncolytic adenovirus for cancer therapy is still a
challenge. Mesenchymal stem cells as cell carriers have gained increasing attention in drug …

Oncolytic viruses (OVs) are emerging cancer immunotherapy. Despite notable successes in
the treatment of some tumors, OV therapy for central nervous system cancers has failed to …

Adenoviral vectors (AdVs) have attracted much attention in the fields of vaccine
development and treatment for diseases such as genetic disorders and cancer. In this …

Oncolytic virotherapy has currently emerged as a powerful therapeutic approach in cancer
treatment. Although the history of using viruses goes back to the early 20th century, the …

Background Osteosarcoma is the most common malignant solid tumor that affects bones,
however, survival rates of patients with relapsed osteosarcoma have not improved in the last …

Oncolytic viruses (OVs) have emerged as a very promising anti-cancer therapeutic strategy
in the past decades. However, despite their pre-clinical promise, many OV clinical …

The development of oncolytic viruses (OVs) has increased significantly in the past 20 years,
with many candidates entering clinical trials and three of them receiving approval for some …

Background and aims Several oncolytic viruses applications have been approved in the
clinic or in different phases of clinical trials. However, these methods have some rudimentary …